Expert Financial Analysis and Reporting

Investment Thesis Investors have turned a thumbs down on the proposed acquisition of Celgene as there was an immediate 14% plunge in the stock price of BMY to $45. Investors are concerned about the patent situation with Celgene’s Revlimid which represents about 64% of CELG sales. The key patent protection on Revlimid expires in 2027, […]

Key Points Investors have turned a thumbs down on the proposed acquisition of Celgene resulting in a 14% plunge in the stock price of BMY to $45. This is because Revlimid represents about 64% of CELG sales and by 2027 or so, generic competition will erode most of its sales. The Revlimid concern was reflected […]

Investment Opinion Conceptual Reason for Recommendation My recommendation of Bristol-Myers Squibb is in contrast to the small, not well-researched biotechnology companies on which I usually focus. BMY is a large, complex and well analyzed multinational company with a broad product portfolio and burgeoning pipeline. It requires as much time to analyze as several small biotechnology […]

The stoppage at an interim analysis of Bristol-Myers Squibb’s’ CHECKMATE-214 trial provides meaningful information into assessing the potential fro success of Northwest Biotherapeutics’ phase 3, DCVax-L trial. CHECKMATE-214 compared a combination the immunotherapy drugs Opdivo and Yervoy to Sutent (standard of care) in previously untreated, advanced or metastatic renal cell carcinoma (RCC). The trial was […]

The New Press Release Bristol-Myers Squibb’s stock declined from $55.49 at the close on Thursday January 19 to $49.23 at the close on Friday January 20. This was due to a terse press release on January 20th that read “Bristol-Myers Squibb Company announced today that it has decided not to pursue an accelerated regulatory pathway […]

Investment overview Yesterday, BMY traded down sharply due to President-elect Trump’s statements on drug pricing and Merck’s announcement that the FDA has accepted a sBLA filing for the combination of Keytruda and chemotherapy (pemetrexed plus carboplatin) for the treatment of first-line metastatic or advanced non-squamous NSCLC. This report only deals with the Merck announcement. In […]

Purpose of this Report I last summarized my stock recommendations in a September 12, 2016 report. There has been little change in my thinking or my recommendations since then on most stocks in my universe, but I did issue a Buy on Bristol-Myers Squibb and a sell on Juno Therapeutics. You may want to revisit […]

Background Information on Checkpoint Modulation Let me provide background information that shapes my views on immuno-oncology before I get into my recommendation. The immune system has evolved over more than one billion years as a defense mechanism to protect humans and other life forms from pathogenic organisms that cause disease- notably bacteria, viruses, fungi and […]

Perspective Bristol-Myers Squibb Company announced today that Opdivo had failed to reach its primary endpoint of progression free survival in the CheckMate -026 trial in first line non-small cell lung cancer. This was an open-label, study that randomized 541 patients to receive either Opdivo as monotherapy or investigator’s choice of chemotherapy. Patients enrolled in the […]

Bristol-Myers disclosed on August 1, 2012 that it has suspended a phase II trial in hepatitis C in which BMS-986094, its nucleotide polymerase inhibitor, was being studied in combination with daclatasvir, its NS5a inhibitor. BMS-986094 has been broadly viewed as the cornerstone of BMY’s effort to develop an all oral combination treatment for hepatitis C […]